Synergistic Effects of Exemestane and Aspirin on MCF-7 Human Breast Cancer Cells |
Hu, Li-Xia
(Department of Oncology, The First Affiliated Hospital of Anhui Medical University)
Du, Ying-Ying (Department of Oncology, The First Affiliated Hospital of Anhui Medical University) Zhang, Ying (Department of Geriatrics, The Third Affiliated Hospital of Anhui Medical University) Pan, Yue-Yin (Department of Oncology, The First Affiliated Hospital of Anhui Medical University) |
1 | Abbadessa G, Spaccamiglio A, Sartori ML, et al (2006). The aspirin metabolite, salicylate, inhibits 7,12-dimethylbenz[a] anthracene-DNA adduct formation in breast cancer cells. Int J Oncol, 28, 1131-40. |
2 | Basu GD, Liang WS, Stephan DA, et al (2006). A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cells. Breast Cancer Res, 8, R69. DOI |
3 | Chan AT, Ogino S, Fuchs CS (2007). Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med, 356, 2131-42. DOI |
4 | Chou TC, Talalay P (1984). Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul, 22, 27-55. DOI ScienceOn |
5 | Chulada PC, Thompson MB, Mahler JF, et al (2000). Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res, 60, 4705-8. |
6 | Connolly EM, Harmey JH, O'Grady T, et al (2002). Cyclooxygenase inhibition reduces tumour growth and metastasis in an orthotopic model of breast cancer. Br J Cancer, 87, 231-7. DOI ScienceOn |
7 | Daikoku T, Tranguch S, Chakrabarty A, et al (2007). Extracellular signal-regulated kinase is a target of cyclooxygenase-1-peroxisome proliferator-activated receptor-delta signaling in epithelial ovarian cancer. Cancer Res, 67, 5285-92. DOI |
8 | Daikoku T, Tranguch S, Trofimova IN, et al (2006). Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer. Cancer Res, 66, 2527-31. DOI |
9 | Daikoku T, Wang D, Tranguch S, et al (2005). Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. Cancer Res, 65, 3735-44. DOI |
10 | Davies G, Martin LA, Sacks N, et al (2002). Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention. Ann Oncol, 13, 669-78. DOI |
11 | Diaz-Cruz ES, Shapiro CL, Brueggemeier RW (2005). Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J Clin Endocrinol Metab, 90, 2563-70. DOI ScienceOn |
12 | Gately S (2000). The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev, 19, 19-27. DOI ScienceOn |
13 | Diel P, Smolnikar K, Michna H (1999). The pure antiestrogen ICI 182780 is more effective in the induction of apoptosis and down regulation of BCL-2 than tamoxifen in MCF-7 cells. Breast Cancer Res Treat, 58, 87-97. DOI |
14 | Dong Z, Huang C, Brown RE, et al (1997). Inhibition of activator protein 1 activity and neoplastic transformation by aspirin. J Biol Chem, 272, 9962-70. DOI ScienceOn |
15 | Erovic BM, Woegerbauer M, Pammer J, et al (2008). Strong evidence for up-regulation of cyclooxygenase-1 in head and neck cancer. Eur J Clin Invest, 38, 61-6. |
16 | Geisler J, Lonning PE (2005). Aromatase inhibition: translation into a successful therapeutic approach. Clin Cancer Res, 11, 2809-21. DOI |
17 | Ghosh N, Chaki R, Mandal V, et al (2010). COX-2 as a target for cancer chemotherapy. Pharmacol Rep, 62, 233-44. DOI |
18 | Goldhirsch A, Glick JH, Gelber RD, et al (2005). Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol, 16, 1569-83. DOI ScienceOn |
19 | Gupta RA, Tejada LV, Tong BJ, et al (2003). Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res, 63, 906-11. |
20 | Harris RE, Robertson FM, Abou-Issa HM, et al (1999). Genetic induction and upregulation of cyclooxygenase (COX) and aromatase (CYP19): an extension of the dietary fat hypothesis of breast cancer. Med Hypotheses, 52, 291-2. DOI ScienceOn |
21 | Hwang D, Scollard D, Byrne J, et al (1998). Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst, 90, 455-60. DOI ScienceOn |
22 | Hiraga T, Myoui A, Choi ME, et al (2006). Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer. Cancer Res, 66, 2067-73. DOI |
23 | Howe LR (2007). Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res, 9, 210. DOI |
24 | Howe LR, Lippman SM (2008). Modulation of breast cancer risk by nonsteroidal anti-inflammatory drugs. J Natl Cancer Inst, 100, 1420-3. DOI |
25 | Janicke F (2007). Continuing with letrozole offers greater benefits. J Cancer Res Clin Oncol, 133, 445-53. DOI |
26 | Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. DOI |
27 | Juuti A, Louhimo J, Nordling S, et al (2006). Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer. J Clin Pathol, 59, 382-6. DOI |
28 | Kanthamneni N, Chaudhary A, Wang J, et al (2010). Nanoparticulate delivery of novel drug combination regimens for the chemoprevention of colon cancer. Int J Oncol, 37, 177-85. |
29 | Kirschenbaum A, Klausner AP, Lee R, et al (2000). Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology, 56, 671-6. DOI |
30 | Kundu N, Fulton AM (2002). Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer. Cancer Res, 62, 2343-6. |
31 | Masferrer JL, Leahy KM, Koki AT, et al (2000). Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res, 60, 1306-11. |
32 | Leahy KM, Ornberg RL, Wang Y, et al (2002). Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res, 62, 625-31. |
33 | Liu XH, Rose DP (1996). Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res, 56, 5125-7. |
34 | Lu M, Strohecker A, Chen F, et al (2008). Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels. Clin Cancer Res, 14, 3168-76. DOI ScienceOn |
35 | McFadden DW, Riggs DR, Jackson BJ, et al (2006). Additive effects of Cox-1 and Cox-2 inhibition on breast cancer in vitro. Int J Oncol, 29, 1019-23. |
36 | Mohseni H, Zaslau S, McFadden D, et al (2004). COX-2 inhibition demonstrates potent anti-proliferative effects on bladder cancer in vitro. J Surg Res, 119, 138-42. DOI |
37 | Pillinger MH, Capodici C, Rosenthal P, et al (1998). Modes of action of aspirin-like drugs: salicylates inhibit erk activation and integrin-dependent neutrophil adhesion. Proc Natl Acad Sci U S A, 95, 14540-5. DOI |
38 | Riemsma R, Forbes CA, Kessels A, et al (2010). Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer. Breast Cancer Res Treat, 123, 9-24. DOI |
39 | Ristimaki A, Sivula A, Lundin J, et al (2002). Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res, 62, 632-5. |
40 | Ruvolo PP, Deng X, May WS (2001). Phosphorylation of Bcl2 and regulation of apoptosis. Leukemia, 15, 515-22. |
41 | Smith IE, Dowsett M (2003). Aromatase inhibitors in breast cancer. N Engl J Med, 348, 2431-42. DOI |
42 | Sales KJ, Katz AA, Howard B, et al (2002). Cyclooxygenase-1 is up-regulated in cervical carcinomas: autocrine/paracrine regulation of cyclooxygenase-2, prostaglandin e receptors, and angiogenic factors by cyclooxygenase-1. Cancer Res, 62, 424-32. |
43 | Sheng H, Shao J, Morrow JD, et al (1998). Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res, 58, 362-6. |
44 | Slattery ML, Curtin K, Baumgartner R, et al (2007). IL6, aspirin, nonsteroidal anti-inflammatory drugs, and breast cancer risk in women living in the southwestern United States. Cancer Epidemiol Biomarkers Prev, 16, 747-55. DOI |
45 | Son DS, Wilson AJ, Parl AK, et al (2010). The effects of the histone deacetylase inhibitor romidepsin (FK228) are enhanced by aspirin (ASA) in COX-1 positive ovarian cancer cells through augmentation of p21. Cancer Biol Ther, 9, 928-35. DOI |
46 | Surowiak P, Materna V, Matkowski R, et al (2005). Relationship between the expression of cyclooxygenase 2 and MDR1/Pglycoprotein in invasive breast cancers and their prognostic significance. Breast Cancer Res, 7, R862-70. DOI |
47 | Taketo MM (1998). Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J Natl Cancer Inst, 90, 1609-20. DOI |
48 | Timoshenko AV, Xu G, Chakrabarti S, et al (2003). Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells. Exp Cell Res, 289, 265-74. DOI |
49 | Tsatsanis C, Androulidaki A, Venihaki M, et al (2006). Signalling networks regulating cyclooxygenase-2. Int J Biochem Cell Biol, 38, 1654-61. DOI ScienceOn |
50 | Van Dyke AL, Cote ML, Prysak G, et al (2008). Regular adult aspirin use decreases the risk of non-small cell lung cancer among women. Cancer Epidemiol Biomarkers Prev, 17, 148-57. DOI |
51 | Winer EP, Hudis C, Burstein HJ, et al (2005). American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol, 23, 619-29. DOI |
52 | Xu XM, Sansores-Garcia L, Chen XM, et al (1999). Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate. Proc Natl Acad Sci U S A, 96, 5292-7. DOI ScienceOn |